Cite
HARVARD Citation
Andronis, L. et al. (2017). Cost‐effectiveness of zoledronic acid and strontium‐89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate‐refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747). BJU international. pp. 522-529. [Online].